Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Current Assets (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Current Assets for 13 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 25.44% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.0 million, a 25.44% decrease, with the full-year FY2025 number at $14.0 million, down 25.44% from a year prior.
  • Current Assets was $14.0 million for Q4 2025 at Ekso Bionics Holdings, down from $14.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $54.6 million in Q1 2021 to a low of $14.0 million in Q4 2025.
  • A 5-year average of $29.6 million and a median of $23.5 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 288.32% in 2021, then crashed 39.16% in 2023.
  • Ekso Bionics Holdings' Current Assets stood at $47.8 million in 2021, then tumbled by 35.06% to $31.0 million in 2022, then tumbled by 34.89% to $20.2 million in 2023, then decreased by 6.75% to $18.8 million in 2024, then dropped by 25.44% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Current Assets are $14.0 million (Q4 2025), $14.8 million (Q3 2025), and $16.0 million (Q2 2025).